Secondary analysis of CASTLE-HTx (194 patients with end-stage heart failure and AF): catheter ablation plus GDMT vs medical therapy alone gave a 3-year net treatment benefit of 35.3% (win odds 2.09), driven mainly by death and HF hospitalisation.
Secondary analysisn = 194
Moersdorf et al. Catheter ablation in end-stage heart failure with atrial fibrillation: an hierarchical endpoint analysis of the CASTLE-HTx trial